
|Articles|November 26, 2014 (Updated: April 18, 2020)
- Immunotherapy (Issue 4)
- Volume 4
- Issue 1
Potential Immunotherapies for Head and Neck Cancers
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
Barbara Burtness, MD, Clinical Research Program Leader, Head and Neck Cancers Program,Co-Director, Developmental Therapeutics Research Program,Professor of Medicine (Medical Oncology), Yale Cancer Center, discusses potential immunotherapy agents that may assist in the treatment of head and neck cancers.
<<<
Articles in this issue
over 11 years ago
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Questionover 11 years ago
Programs Prepare for Immuno-Oncology in Clinical Settingover 11 years ago
Right Patient for Immunotherapy in NSCLC Exploredover 11 years ago
Weight May Affect Toxicity of Immunotherapiesover 11 years ago
Adverse Events Associated With Immunotherapy in Lung Cancerover 11 years ago
Immunotherapy Potential Option in Mesothelioma Treatmentover 11 years ago
Immunotherapies for Prostate CancerRelated Content
Advertisement




Subcutaneous Amivantamab Nabs Breakthrough Therapy Designation in HNSCC
Published: | Updated:

Induction Nivolumab Misses Feasibility Goal in Oropharyngeal Cancer
Published: | Updated:



























